pharmaceutical daily

$33.1M in Rubraca® (rucaparib) global sales for the first quarter of 2018 Updated data on 52 patients with BRCA-mutant mCRPC…

BOSTON–(BUSINESS WIRE)–Kyn Therapeutics, a clinical-stage biotechnology company developing highly differentiated cancer immunotherapies, today announced the appointment of Jeffrey Ecsedy, Ph.D.,…

CAMBRIDGE, England & BOSTON–(BUSINESS WIRE)–Bicycle Therapeutics, a biotechnology company pioneering a new class of therapeutics based on its proprietary bicyclic…

AUSTIN, Texas–(BUSINESS WIRE)–Elligo Health Research, an integrated research organization (IRO), announced today $20 million in Series C funding led by…

DALLAS–(BUSINESS WIRE)–Peloton Therapeutics, Inc., a clinical-stage biopharmaceutical company advancing first-in-class oral medicines for cancer and other serious conditions, announced that…

Experienced attorney to lead high-value intellectual property procurement and protection BERKELEY, Calif.–(BUSINESS WIRE)–lt;a href="https://twitter.com/hashtag/biochemicals?src=hash" target="_blank"gt;#biochemicalslt;/agt;–Lygos, Inc., a full-stack producer of…

Promotion Reflects Vollmer’s Expanding Leadership Role with Company Since its 2014 Founding McKINNEY, Texas–(BUSINESS WIRE)–lt;a href="https://twitter.com/hashtag/soleohealthnamesCraigVollmerchiefcommericalofficer?src=hash" target="_blank"gt;#soleohealthnamesCraigVollmerchiefcommericalofficerlt;/agt;–Soleo Health, an innovative…

– Announces USAN selection of omidubicel as nonproprietary name for company’s investigational NAM-expanded hematopoietic stem cells (formerly known as NiCord®)…

Patients across all age subgroups treated with ozanimod lost less cortical grey matter volume than did those treated with interferon…

Q3’19 revenue of $617.5 million decreased 2% as-reported, but increased 2% in constant currency, from Q3’18, while Q3’19 YTD revenue…